文献速递眼底病与葡萄膜炎

真实世界环境下抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性的结局

Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
PubMed 文献 · Br J Ophthalmol · 2017-10-26

回顾性单中心研究纳入2008至2013年间接受三针负荷方案抗VEGF治疗的1117例新生血管性年龄相关性黄斑变性患者共1349眼,3年随访平均注射15.3次,视力较基线变化为+2、+2和±0个ETDRS字母,护士与医生注射的眼部严重不良事件发生率无差异,眼内炎发生率为0.086%。

要点

  • 真实世界3年随访中,抗VEGF治疗使视力维持于基线水平(±0个ETDRS字母),平均注射15.3次。
  • 护士与医生注射的眼部严重不良事件发生率无差异,眼内炎发生率为0.086%。
  • 基线视力与视力变化呈负相关。

核心结论

  • 在真实世界临床实践中,3年随访期间平均注射15.3次抗VEGF后,视力维持于基线水平(±0个ETDRS字母)。

研究设计与样本

  • 回顾性、单中心研究,评估2008年至2013年间接受抗VEGF治疗且采用三针负荷方案的新生血管性年龄相关性黄斑变性患者的病历资料。
  • 共纳入1117例患者1349眼,接受总计11562次玻璃体腔抗VEGF注射。

主要发现

  • 患者平均基线Snellen视力为0.32,第1、2、3年视力较基线平均变化分别为+2、+2和±0个ETDRS字母。
  • 第1、2、3年平均注射次数分别为5.7、4.7和4.9次。
  • 21%的患者接受双眼治疗,基线视力与视力变化呈负相关。
  • 眼内炎发生率为0.086%,护士与医生注射的眼部严重不良事件发生率无差异。
  • 每1000名居民中玻璃体腔注射次数为9次,每1000名65岁以上居民中为45次。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) in the real-life setting and to compare incidence of ocular serious adverse events (SAE) after injections administered by nurses and physicians. METHODS: Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for nAMD between 2008 and 2013 with three-loading-dose regimen were evaluated. Outcome measures were baseline visual acuity (VA), change in VA, number of intravitreal injections, incidence of ocular SAE and patients' baseline characteristics affecting VA change. In addition, the number of injections per 1000 citizens living in the serving area and per individuals over 65 years old were estimated. RESULTS: 1349 eyes in 1117 patients received a total of 11 562 intravitreal anti-VEGF injections. Twenty-one per cent of patients received treatment for both eyes. The mean baseline Snellen VA was 0.32. The mean change of VA from baseline was +2, +2 and ±0 Early Treatment Diabetic Retinopathy Study letters and the mean numbers of injections were 5.7, 4.7 and 4.9 at years 1, 2 and 3, respectively. There was a negative correlation between baseline VA and change of VA. Incidence of endophthalmitis was 0.086%. No difference in the incidence of ocular SAE was identified between injections given by nurses or by physicians. The number of intravitreal injections per all citizens was 9 per 1000 inhabitants and 45 per 1000 inhabitants over 65 years. CONCLUSION: The VA was maintained at the baseline level (±0 letters) with the mean of 15.3 anti-VEGF injections in real-world clinical practice during 3-year follow-up.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kataja M, Hujanen P, Huhtala H, et al. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. Br J Ophthalmol. 2017. PMID: 29074495. doi:10.1136/bjophthalmol-2017-311055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。